Market Intelligence, Clinical Progress, and High-Purity Reagents for Alloimmunization and Autoimmune Hematology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RHD drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RHD/CD240D Recombinant Protein HEK293 Expressed, Sequence Verified, High Purity (>95%). |
View RHD Products |
| Gene Delivery | RHD/CD240D Lentivirus Premade Particles Full-length ORF for stable cell line generation (Conformation Preservation). |
View RHD Products |
| Benchmark Ab | Anti-RHD Recombinant Antibody Positive control derived from clinical-grade sequences (e.g., Rozrolimupab). |
View RHD Products |
| Validator | RHD/CD240D siRNA Set For target knockdown verification in model systems. |
View RHD Products |
| Related Target A | RHCE Crucial counter-screening target due to high sequence homology (>92%). |
View RHCE Products |
| Related Target B | CD47 Associated with the Rh membrane complex; involved in RBC clearance pathways. |
View CD47 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| 12-Pass Transmembrane Conformation | Lentivirus Premade Particles for stable cell line expression to preserve native 3D structure. |
| Subfamily Off-Target Cross-Reactivity (RHCE) | RHCE counterpart screening tools available to verify RHD-specific binding. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies available as positive controls. |
| False Positives | Validated siRNA sets included for specific target knockdown validation. |
Live RHD/CD240D R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RHD/CD240D therapeutics is intensifying, with major players shifting focus from traditional plasma-derived polyclonal anti-D immunoglobulins to recombinant monoclonal antibody cocktails. As first-generation therapies reach maturity, the next wave of R&D is targeting high-affinity, recombinant multi-antibody formulations to completely eliminate reliance on donor plasma and mitigate viral contamination risks.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Recombinant mAb Cocktails | Symphogen, Kamada, GigaGen | Hemolytic Disease of the Fetus and Newborn (HDFN), ITP | Specificity Screening (Need RHD vs. RHCE cell-based assays) |
| Monoclonal Antibodies | LFB Group, Kedrion | Rh Alloimmunization Prevention | Conformational Binding (Need Lentivirus for Stable Cell Lines) |
| Diagnostics / Typing Reagents | Ortho Clinical Diagnostics, Grifols | Blood Grouping, Transfusion Medicine | High-affinity control antibodies and sequence-verified targets |